Overview

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

Status:
Completed

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential regadenoson SPECT images without exercise.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Treatments:

Regadenoson